Skip to main content

Innovative medicines in the pipeline

Only 5 % of rare diseases have approved medicines. The need for innovative treatments is, therefore, high. A strong pipeline and expanded access are key elements of our commitment to patients.

Interim Report Q3 2025

Sobi intends to publish its Q3 2025 report on 23 October.

Press releases

A new therapy’s path to the patient

Bringing new therapies to patients involves navigating long timelines and inherent risks, making it a complex and costly endeavor. Discover how we prioritise patient access to treatment while addressing these development challenges.

Focus on Rare diseases

More than 10,000 rare diseases have been identified, with more being discovered every day. While many rare diseases are very uncommon, together they affect 400 million people worldwide.

Loading...
Sobi_HQ_office_building-cut.jpg

Head office

[email protected]

+46 8 697 20 00

Visiting address:
Norra Stationsgatan 93A
Stockholm, Sweden

Careers

Take a look at our job opportunities.